Fakuade Funsho Emmanuel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fakuade Funsho Emmanuel has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Niels Voigt
DZHK (German Centre for Cardiovascular Research), Partner Site Lower Saxony, Göttingen, Germany
9 shared publications - Fitzwilliam Seibertz
Institute of Pharmacology and Toxicology, University Medical Center Göttingen, Georg-August University Göttingen, Göttingen, Germany
5 shared publications - Julius Ryan D. Pronto
Institute of Pharmacology and Toxicology (J.R.D.P., F.E.M., F.E.F., D.B., P.B., P.J.S., K.R., S.K., N.V.), University Medical Center Göttingen, Germany
4 shared publications - Aiste Liutkute
Institute of Pharmacology and Toxicology, University Medical Center Göttingen, Georg-August University Göttingen, Göttingen, Germany
3 shared publications - Aschraf El-Essawi
Department of Thoracic and Cardiovascular Surgery, University Medical Center Göttingen, Göttingen, Germany
3 shared publications - Fleur E. Mason
Institute of Pharmacology and Toxicology (J.R.D.P., F.E.M., F.E.F., D.B., P.B., P.J.S., K.R., S.K., N.V.), University Medical Center Göttingen, Germany
3 shared publications
Latest Publications
- Open Access
- 7 November 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (11) , 1333-1352
Impaired Atrial Mitochondrial Calcium Handling in Patients With Atrial Fibrillation
BACKGROUND: Mitochondrial calcium (Ca 2+ ) is a key regulator of cardiac energetics by stimulating the tricarboxylic acid cycle during elevated workload. Atrial fibrillation (AF) is associated with a reduction in cytosolic Ca 2+ transient amplitude, but its effect on mitochondrial Ca 2+ handling and cellular redox state has not been explored. METHODS: Cardiac myocytes isolated from patient-derived right atrial biopsies were subjected to workload transitions using patch-clamp stimulation and β-adrenergic stimulation (isoproterenol). In conjunction, nicotinamide adenine dinucleotide (phosphate)/flavin adenine dinucleotide (NAD[P]H/FAD) autofluorescence, cytosolic and mitochondrial [Ca 2+ ] were monitored using epifluorescence microscopy. Sarcoplasmic reticulum and mitochondria were imaged using electron microscopy and tomography and stimulated emission depletion microscopy. The effects of the mitochondrial Ca 2+ uptake enhancer ezetimibe on proarrhythmic activity in atrial myocytes and on AF burden in patients were investigated. RESULTS: Mitochondrial Ca 2+ accumulation during increased workload was blunted in AF, and was associated with impaired regeneration of nicotinamide adenine dinucleotide and flavin adenine dinucleotide. Nanoscale imaging revealed spatial disorganization of sarcoplasmic reticulum and mitochondria, associated with microtubule destabilization. This was confirmed in human induced pluripotent stem cell–derived cardiac myocytes, where treatment with the microtubule destabilizer nocodazole displaced mitochondria and increased proarrhythmic Ca 2+ sparks, which were rescued by MitoTEMPO. Ezetimibe also reduced the occurrence of arrhythmogenic Ca 2+ release events both in AF myocytes and nocodazole-treated human induced pluripotent stem cell–derived cardiac myocytes. Retrospective patient analysis also revealed a reduced AF burden in patients on ezetimibe treatment. CONCLUSIONS: Mitochondrial Ca 2+ uptake and accumulation are impaired in atrial myocytes from patients with AF. The disturbed spatial association between sarcoplasmic reticulum and mitochondria driven by destabilized microtubules may underlie impaired Ca 2+ transfer in AF. Enhancing mitochondrial Ca 2+ uptake potentially protects against arrhythmogenic events.
- 7 November 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 137 (11) , 1333-1352
Open AccessImpaired Atrial Mitochondrial Calcium Handling in Patients With Atrial Fibrillation
BACKGROUND: Mitochondrial calcium (Ca 2+ ) is a key regulator of cardiac energetics by stimulating the tricarboxylic acid cycle during elevated workload. Atrial fibrillation (AF) is associated with a reduction in cytosolic Ca 2+ transient amplitude, but its effect on mitochondrial Ca 2+ handling and cellular redox state has not been explored. METHODS: Cardiac myocytes isolated from patient-derived right atrial biopsies were subjected to workload transitions using patch-clamp stimulation and β-adrenergic stimulation (isoproterenol). In conjunction, nicotinamide adenine dinucleotide (phosphate)/flavin adenine dinucleotide (NAD[P]H/FAD) autofluorescence, cytosolic and mitochondrial [Ca 2+ ] were monitored using epifluorescence microscopy. Sarcoplasmic reticulum and mitochondria were imaged using electron microscopy and tomography and stimulated emission depletion microscopy. The effects of the mitochondrial Ca 2+ uptake enhancer ezetimibe on proarrhythmic activity in atrial myocytes and on AF burden in patients were investigated. RESULTS: Mitochondrial Ca 2+ accumulation during increased workload was blunted in AF, and was associated with impaired regeneration of nicotinamide adenine dinucleotide and flavin adenine dinucleotide. Nanoscale imaging revealed spatial disorganization of sarcoplasmic reticulum and mitochondria, associated with microtubule destabilization. This was confirmed in human induced pluripotent stem cell–derived cardiac myocytes, where treatment with the microtubule destabilizer nocodazole displaced mitochondria and increased proarrhythmic Ca 2+ sparks, which were rescued by MitoTEMPO. Ezetimibe also reduced the occurrence of arrhythmogenic Ca 2+ release events both in AF myocytes and nocodazole-treated human induced pluripotent stem cell–derived cardiac myocytes. Retrospective patient analysis also revealed a reduced AF burden in patients on ezetimibe treatment. CONCLUSIONS: Mitochondrial Ca 2+ uptake and accumulation are impaired in atrial myocytes from patients with AF. The disturbed spatial association between sarcoplasmic reticulum and mitochondria driven by destabilized microtubules may underlie impaired Ca 2+ transfer in AF. Enhancing mitochondrial Ca 2+ uptake potentially protects against arrhythmogenic events.
- Open Access
- 9 September 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (13) , 1609-1621
Cytosolic calcium handling signature: integration with clinical predictors enhances prediction of post-operative atrial fibrillation
Background and Aims: Atrial fibrillation (AF) is a prevalent complication after cardiac surgery, worsening patient outcomes. Considering the established role of Ca2+-handling abnormalities in AF pathogenesis, this study aimed to evaluate if integrating cytosolic Ca2+-handling measurements with clinical risk factors enhances the risk prediction of post-operative AF. Methods: Clinical data from 558 patients undergoing cardiac surgery without pre-existing AF from two centres were analysed. From 94 of these patients, atrial cardiomyocytes were isolated from collected right atrial appendages and Ca2+ handling (L-type Ca2+ current, intracellular Ca2+ concentration) was assessed using patch-clamp. The predictive performance of combining both clinical and single-cell Ca2+ handling parameters was tested using sequential feature selection and logistic regression models. Results: Single-cell Ca2+-handling parameters through cluster analysis correlated with post-operative AF development and several cardiac diseases. Integration of Ca2+-handling parameters into a new post-operative AF risk prediction model improved its predictive accuracy by increasing the areas under the receiver operating characteristic (ROC) curves from 0.69 to 0.71 in the training and 0.76 to 0.79 in the validation cohort. Systolic Ca2+ level, along with clinical parameters such as age, left atrial dilatation, valvular heart disease, impaired renal function, and serum magnesium, was identified as an independent risk factor for post-operative AF. Additionally, a predictive score for AF occurrence at discharge and during rehabilitation has been developed, with area under the curve (AUC) values of 0.84 and 0.71, respectively. Incorporating the occurrence of AF during the immediate post-operative period as an additional predictor significantly enhanced the prediction of AF at discharge, achieving an AUC value of 0.94. Conclusions: Integrating cellular Ca2+ handling signature with clinical predictors improves the prediction of post-operative AF, highlighting the potential of incorporating functional cellular data into clinical risk models.
- 9 September 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (13) , 1609-1621
Open AccessCytosolic calcium handling signature: integration with clinical predictors enhances prediction of post-operative atrial fibrillation
Background and Aims: Atrial fibrillation (AF) is a prevalent complication after cardiac surgery, worsening patient outcomes. Considering the established role of Ca2+-handling abnormalities in AF pathogenesis, this study aimed to evaluate if integrating cytosolic Ca2+-handling measurements with clinical risk factors enhances the risk prediction of post-operative AF. Methods: Clinical data from 558 patients undergoing cardiac surgery without pre-existing AF from two centres were analysed. From 94 of these patients, atrial cardiomyocytes were isolated from collected right atrial appendages and Ca2+ handling (L-type Ca2+ current, intracellular Ca2+ concentration) was assessed using patch-clamp. The predictive performance of combining both clinical and single-cell Ca2+ handling parameters was tested using sequential feature selection and logistic regression models. Results: Single-cell Ca2+-handling parameters through cluster analysis correlated with post-operative AF development and several cardiac diseases. Integration of Ca2+-handling parameters into a new post-operative AF risk prediction model improved its predictive accuracy by increasing the areas under the receiver operating characteristic (ROC) curves from 0.69 to 0.71 in the training and 0.76 to 0.79 in the validation cohort. Systolic Ca2+ level, along with clinical parameters such as age, left atrial dilatation, valvular heart disease, impaired renal function, and serum magnesium, was identified as an independent risk factor for post-operative AF. Additionally, a predictive score for AF occurrence at discharge and during rehabilitation has been developed, with area under the curve (AUC) values of 0.84 and 0.71, respectively. Incorporating the occurrence of AF during the immediate post-operative period as an additional predictor significantly enhanced the prediction of AF at discharge, achieving an AUC value of 0.94. Conclusions: Integrating cellular Ca2+ handling signature with clinical predictors improves the prediction of post-operative AF, highlighting the potential of incorporating functional cellular data into clinical risk models.
- Open Access
- 25 August 2025
- Published by Wiley in The Journal of Physiology
- Vol. 604 (16) , 6858-6871
Blebbistatin reduces calcium buffering in cardiomyocytes: Consequences for cellular electrophysiology
Blebbistatin is an excitation–contraction uncoupling agent commonly used in cardiac optical mapping; however, it has been reported to influence cardiac myofilament Ca2+ sensitivity. As primary contributors to Ca2+ buffering within cardiomyocytes, cardiac myofilaments play a critical role, and even minor disruptions in intracellular Ca2+ buffering significantly alter the free Ca2+ concentration. In this study, we investigated the effect of blebbistatin, a myosin II ATPase inhibitor, on intracellular Ca2+ buffering and cellular electrophysiology in induced pluripotent stem cell‐derived atrial cardiomyocytes. Simultaneous whole‐cell ruptured patch‐clamp and fluorescence microscopy techniques were used to assess intracellular Ca2+ handling, in addition to automated high‐throughput patch‐clamp to investigate ion channel function. Comprehensive analysis of Ca2+ buffering revealed that blebbistatin (10 µmol/l) causes a significant increase in buffer dissociation constant, suggesting decreased affinity of Ca2+ buffers. Furthermore, systolic and diastolic Ca2+ levels, sarcoplasmic reticulum Ca2+ leak and the incidence of spontaneous Ca2+ release events were significantly higher upon blebbistatin treatment. Although there was lack of impact on INa and ICa,L peak density, Ca2+‐dependent inactivation of ICa,L was significantly enhanced, and IK1 density was significantly smaller after blebbistatin. Importantly, these effects were reversed after chelation of intracellular Ca2+ with EGTA. Our observations indicate that blebbistatin reduces Ca2+ buffering, which, in turn, causes changes in cellular electrophysiology in cardiomyocytes. image Key points: Intracellular Ca2+ buffering plays an important role in determining Ca2+ dynamics in cardiomyocytes. Blebbistatin, an excitation–contraction uncoupling agent widely used in experimental studies, decreases the affinity of intracellular Ca2+ buffers, as indicated by an increased buffer dissociation constant. Blebbistatin leads to higher systolic and diastolic Ca2+ levels and increased sarcoplasmic reticulum Ca2+ leak. Blebbistatin enhances L‐type Ca2+ current (ICa,L) Ca2+‐dependent inactivation and reduces inward rectifier potassium current (IK1) density, while INa and ICa,L remain unchanged. The effects of blebbistatin are mitigated by chelation of intracellular Ca2+ with EGTA, showing that they are secondary to altered Ca2+ buffering.
- 25 August 2025
- Published by Wiley in The Journal of Physiology
- Vol. 604 (16) , 6858-6871
Open AccessBlebbistatin reduces calcium buffering in cardiomyocytes: Consequences for cellular electrophysiology
Blebbistatin is an excitation–contraction uncoupling agent commonly used in cardiac optical mapping; however, it has been reported to influence cardiac myofilament Ca2+ sensitivity. As primary contributors to Ca2+ buffering within cardiomyocytes, cardiac myofilaments play a critical role, and even minor disruptions in intracellular Ca2+ buffering significantly alter the free Ca2+ concentration. In this study, we investigated the effect of blebbistatin, a myosin II ATPase inhibitor, on intracellular Ca2+ buffering and cellular electrophysiology in induced pluripotent stem cell‐derived atrial cardiomyocytes. Simultaneous whole‐cell ruptured patch‐clamp and fluorescence microscopy techniques were used to assess intracellular Ca2+ handling, in addition to automated high‐throughput patch‐clamp to investigate ion channel function. Comprehensive analysis of Ca2+ buffering revealed that blebbistatin (10 µmol/l) causes a significant increase in buffer dissociation constant, suggesting decreased affinity of Ca2+ buffers. Furthermore, systolic and diastolic Ca2+ levels, sarcoplasmic reticulum Ca2+ leak and the incidence of spontaneous Ca2+ release events were significantly higher upon blebbistatin treatment. Although there was lack of impact on INa and ICa,L peak density, Ca2+‐dependent inactivation of ICa,L was significantly enhanced, and IK1 density was significantly smaller after blebbistatin. Importantly, these effects were reversed after chelation of intracellular Ca2+ with EGTA. Our observations indicate that blebbistatin reduces Ca2+ buffering, which, in turn, causes changes in cellular electrophysiology in cardiomyocytes. image Key points: Intracellular Ca2+ buffering plays an important role in determining Ca2+ dynamics in cardiomyocytes. Blebbistatin, an excitation–contraction uncoupling agent widely used in experimental studies, decreases the affinity of intracellular Ca2+ buffers, as indicated by an increased buffer dissociation constant. Blebbistatin leads to higher systolic and diastolic Ca2+ levels and increased sarcoplasmic reticulum Ca2+ leak. Blebbistatin enhances L‐type Ca2+ current (ICa,L) Ca2+‐dependent inactivation and reduces inward rectifier potassium current (IK1) density, while INa and ICa,L remain unchanged. The effects of blebbistatin are mitigated by chelation of intracellular Ca2+ with EGTA, showing that they are secondary to altered Ca2+ buffering.
- Open Access
- 8 October 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (40) , 4349-4351
Cardiac arrhythmias: the growing role of autoantibodies in diagnosis and treatment
Role of autoantibodies against atrial and ventricular ion channels in cardiac arrhythmias and their therapeutic potential. Autoantibodies targeting various cardiac ion channels can have inhibitory (−) and stimulatory (+) effects on depolarizing (purple: INa,peak and ICa,L) and repolarizing (green: IK) ion currents, contributing to pathogenesis of various cardiac arrhythmias, including atrial fibrillation (AF). Additionally, autoantibodies may offer opportunities to develop specific and personalized antiarrhythmic therapeutic approaches. For a detailed explanation, please refer to the text. INa,peak, peak sodium current; ICa,L, L-type-calcium current; IK, potassium current; QTc, corrected QT-interval; Tdp, Torsades de pointes tachycardia.
- 8 October 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (40) , 4349-4351
Open AccessCardiac arrhythmias: the growing role of autoantibodies in diagnosis and treatment
Role of autoantibodies against atrial and ventricular ion channels in cardiac arrhythmias and their therapeutic potential. Autoantibodies targeting various cardiac ion channels can have inhibitory (−) and stimulatory (+) effects on depolarizing (purple: INa,peak and ICa,L) and repolarizing (green: IK) ion currents, contributing to pathogenesis of various cardiac arrhythmias, including atrial fibrillation (AF). Additionally, autoantibodies may offer opportunities to develop specific and personalized antiarrhythmic therapeutic approaches. For a detailed explanation, please refer to the text. INa,peak, peak sodium current; ICa,L, L-type-calcium current; IK, potassium current; QTc, corrected QT-interval; Tdp, Torsades de pointes tachycardia.
- Open Access
- 13 August 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (7) , 544-559
Impaired Intracellular Calcium Buffering Contributes to the Arrhythmogenic Substrate in Atrial Myocytes From Patients With Atrial Fibrillation
BACKGROUND: Alterations in the buffering of intracellular Ca 2+ , for which myofilament proteins play a key role, have been shown to promote cardiac arrhythmia. It is interesting that although studies report atrial myofibrillar degradation in patients with persistent atrial fibrillation (persAF), the intracellular Ca 2+ buffering profile in persAF remains obscure. Therefore, we aimed to investigate the intracellular buffering of Ca 2+ and its potential arrhythmogenic role in persAF. METHODS: Transmembrane Ca 2+ fluxes (patch-clamp) and intracellular Ca 2+ signaling (fluo-3-acetoxymethyl ester) were recorded simultaneously in myocytes from right atrial biopsies of sinus rhythm (Ctrl) and patients with persAF, alongside human atrial subtype induced pluripotent stem cell–derived cardiac myocytes (iPSC-CMs). Protein levels were quantified by immunoblotting of human atrial tissue and induced pluripotent stem cell–derived cardiac myocytes. Mouse whole heart and atrial electrophysiology were measured on a Langendorff system. RESULTS: Cytosolic Ca 2+ buffering was decreased in atrial myocytes of patients with persAF because of a depleted amount of Ca 2+ buffers. In agreement, protein levels of selected Ca 2+ binding myofilament proteins, including cTnC (cardiac troponin C), a major cytosolic Ca 2+ buffer, were significantly lower in patients with persAF. Small interfering RNA (siRNA)–mediated knockdown of cTnC (si-cTNC) in atrial iPSC-CM phenocopied the reduced cytosolic Ca 2+ buffering observed in persAF. Si-cTnC treated atrial iPSC-CM exhibited a higher predisposition to spontaneous Ca 2+ release events and developed action potential alternans at low stimulation frequencies. Last, indirect reduction of cytosolic Ca 2+ buffering using blebbistatin in an ex vivo mouse whole heart model increased vulnerability to tachypacing-induced atrial arrhythmia, validating the direct mechanistic link between impaired cytosolic Ca 2+ buffering and atrial arrhythmogenesis. CONCLUSIONS: Our findings suggest that loss of myofilament proteins, particularly reduced cTnC protein levels, causes diminished cytosolic Ca 2+ buffering in persAF, thereby potentiating the occurrence of spontaneous Ca 2+ release events and atrial fibrillation susceptibility. Strategies targeting intracellular buffering may represent a promising therapeutic lead in persAF management.
- 13 August 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (7) , 544-559
Open AccessImpaired Intracellular Calcium Buffering Contributes to the Arrhythmogenic Substrate in Atrial Myocytes From Patients With Atrial Fibrillation
BACKGROUND: Alterations in the buffering of intracellular Ca 2+ , for which myofilament proteins play a key role, have been shown to promote cardiac arrhythmia. It is interesting that although studies report atrial myofibrillar degradation in patients with persistent atrial fibrillation (persAF), the intracellular Ca 2+ buffering profile in persAF remains obscure. Therefore, we aimed to investigate the intracellular buffering of Ca 2+ and its potential arrhythmogenic role in persAF. METHODS: Transmembrane Ca 2+ fluxes (patch-clamp) and intracellular Ca 2+ signaling (fluo-3-acetoxymethyl ester) were recorded simultaneously in myocytes from right atrial biopsies of sinus rhythm (Ctrl) and patients with persAF, alongside human atrial subtype induced pluripotent stem cell–derived cardiac myocytes (iPSC-CMs). Protein levels were quantified by immunoblotting of human atrial tissue and induced pluripotent stem cell–derived cardiac myocytes. Mouse whole heart and atrial electrophysiology were measured on a Langendorff system. RESULTS: Cytosolic Ca 2+ buffering was decreased in atrial myocytes of patients with persAF because of a depleted amount of Ca 2+ buffers. In agreement, protein levels of selected Ca 2+ binding myofilament proteins, including cTnC (cardiac troponin C), a major cytosolic Ca 2+ buffer, were significantly lower in patients with persAF. Small interfering RNA (siRNA)–mediated knockdown of cTnC (si-cTNC) in atrial iPSC-CM phenocopied the reduced cytosolic Ca 2+ buffering observed in persAF. Si-cTnC treated atrial iPSC-CM exhibited a higher predisposition to spontaneous Ca 2+ release events and developed action potential alternans at low stimulation frequencies. Last, indirect reduction of cytosolic Ca 2+ buffering using blebbistatin in an ex vivo mouse whole heart model increased vulnerability to tachypacing-induced atrial arrhythmia, validating the direct mechanistic link between impaired cytosolic Ca 2+ buffering and atrial arrhythmogenesis. CONCLUSIONS: Our findings suggest that loss of myofilament proteins, particularly reduced cTnC protein levels, causes diminished cytosolic Ca 2+ buffering in persAF, thereby potentiating the occurrence of spontaneous Ca 2+ release events and atrial fibrillation susceptibility. Strategies targeting intracellular buffering may represent a promising therapeutic lead in persAF management.
- Open Access
Polycystin-1 loss of function increases susceptibility to atrial fibrillation through impaired DNA damage response
Background The increasing prevalence of atrial fibrillation (AF) and chronic kidney diseases highlights the need for a deeper comprehension of the molecular mechanisms linking them. Mutations in PKD1, the gene encoding Polycystin-1 (PKD1 or PC1), account for 85% of autosomal dominant polycystic kidney disease (ADPKD) cases. This disease often includes cardiac complications such as AF. In cardiomyocytes, PC1 deletion reduces hypertrophic response to pressure overload but promotes baseline ventricular dysfunction, while deletion in fibroblasts ameliorates post-myocardial infarction fibrosis. Despite its known cardiac impact, the role of PC1 in atrial cardiomyocytes and arrhythmias is less understood. Here, we sought to investigate the role of PC1 in AF. Methods We used intracardiac programmed stimulation and optical mapping to evaluate AF inducibility in two mouse models, Pkd1 R3277C, which recapitulates human ADPKD progression, and cardiomyocyte-specific Pkd1 deletion, and their respective controls. Isolated adult mouse atrial cardiomyocytes, human iPSC-derived atrial cardiomyocytes (hiPSC-aCM), and HL-1 cells served as in vitro cellular models. Molecular mechanisms were evaluated using optical mapping and molecular and biochemical approaches. Results Loss-of-function PC1 mutations significantly increased AF susceptibility in vivo and facilitated local reentry in ex vivo left atrial appendages. Comprehensive in vitro experiments supported a direct effect of PC1 in atrial cardiomyocytes. PC1-deficient monolayers exhibited increased arrhythmic events, escalating into reentrant spiral waves post-tachypacing. Transcriptomics analysis revealed PC1-dependent regulation of DNA repair, with PC1 deficiency leading to increased DNA damage under stress. PARP1 inhibitors or nicotinamide riboside, which counteract DNA damage-related metabolic consequences, reduced in vitro arrhythmias PC1-deficient monolayers. Overexpression of the C-terminus of PC1 had the opposite effects in DNA repair genes, suggesting its regulatory effects in atrial cardiomyocytes through retinoblastoma/E2F. Analyses of human atrial tissue from non-ADPKD AF patients showed reduced levels of mature PC1, suggesting a broader relevance of impaired PC1 in AF. Conclusions Impaired PC1 increases in vivo AF inducibility under programmed electrical stimulation and promotes in vitro arrhythmias in hiPSC-aCM and HL-1 cells. Our findings indicate that PC1 protects against DNA damage to reduce AF susceptibility.
Open AccessPolycystin-1 loss of function increases susceptibility to atrial fibrillation through impaired DNA damage response
Background The increasing prevalence of atrial fibrillation (AF) and chronic kidney diseases highlights the need for a deeper comprehension of the molecular mechanisms linking them. Mutations in PKD1, the gene encoding Polycystin-1 (PKD1 or PC1), account for 85% of autosomal dominant polycystic kidney disease (ADPKD) cases. This disease often includes cardiac complications such as AF. In cardiomyocytes, PC1 deletion reduces hypertrophic response to pressure overload but promotes baseline ventricular dysfunction, while deletion in fibroblasts ameliorates post-myocardial infarction fibrosis. Despite its known cardiac impact, the role of PC1 in atrial cardiomyocytes and arrhythmias is less understood. Here, we sought to investigate the role of PC1 in AF. Methods We used intracardiac programmed stimulation and optical mapping to evaluate AF inducibility in two mouse models, Pkd1 R3277C, which recapitulates human ADPKD progression, and cardiomyocyte-specific Pkd1 deletion, and their respective controls. Isolated adult mouse atrial cardiomyocytes, human iPSC-derived atrial cardiomyocytes (hiPSC-aCM), and HL-1 cells served as in vitro cellular models. Molecular mechanisms were evaluated using optical mapping and molecular and biochemical approaches. Results Loss-of-function PC1 mutations significantly increased AF susceptibility in vivo and facilitated local reentry in ex vivo left atrial appendages. Comprehensive in vitro experiments supported a direct effect of PC1 in atrial cardiomyocytes. PC1-deficient monolayers exhibited increased arrhythmic events, escalating into reentrant spiral waves post-tachypacing. Transcriptomics analysis revealed PC1-dependent regulation of DNA repair, with PC1 deficiency leading to increased DNA damage under stress. PARP1 inhibitors or nicotinamide riboside, which counteract DNA damage-related metabolic consequences, reduced in vitro arrhythmias PC1-deficient monolayers. Overexpression of the C-terminus of PC1 had the opposite effects in DNA repair genes, suggesting its regulatory effects in atrial cardiomyocytes through retinoblastoma/E2F. Analyses of human atrial tissue from non-ADPKD AF patients showed reduced levels of mature PC1, suggesting a broader relevance of impaired PC1 in AF. Conclusions Impaired PC1 increases in vivo AF inducibility under programmed electrical stimulation and promotes in vitro arrhythmias in hiPSC-aCM and HL-1 cells. Our findings indicate that PC1 protects against DNA damage to reduce AF susceptibility.
- 7 July 2023
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 133 (2) , 193-195
Vicious Twins: RyR2 Dysfunction and Structural Remodeling
- 7 July 2023
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 133 (2) , 193-195
Vicious Twins: RyR2 Dysfunction and Structural Remodeling
- 7 July 2023
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 133 (2) , E19-E46
An Alternative Mechanism of Subcellular Iron Uptake Deficiency in Cardiomyocytes
Background: Systemic defects in intestinal iron absorption, circulation, and retention cause iron deficiency in 50% of patients with heart failure. Defective subcellular iron uptake mechanisms that are independent of systemic absorption are incompletely understood. The main intracellular route for iron uptake in cardiomyocytes is clathrin-mediated endocytosis. Methods: We investigated subcellular iron uptake mechanisms in patient-derived and CRISPR/Cas–edited induced pluripotent stem cell–derived cardiomyocytes as well as patient-derived heart tissue. We used an integrated platform of DIA-MA (mass spectrometry data-independent acquisition)–based proteomics and signaling pathway interrogation. We employed a genetic induced pluripotent stem cell model of 2 inherited mutations ( TnT [ troponin T ]-R141W and TPM1 [ tropomyosin 1 ]-L185F) that lead to dilated cardiomyopathy (DCM), a frequent cause of heart failure, to study the underlying molecular dysfunctions of DCM mutations. Results: We identified a druggable molecular pathomechanism of impaired subcellular iron deficiency that is independent of systemic iron metabolism. Clathrin-mediated endocytosis defects as well as impaired endosome distribution and cargo transfer were identified as a basis for subcellular iron deficiency in DCM-induced pluripotent stem cell–derived cardiomyocytes. The clathrin-mediated endocytosis defects were also confirmed in the hearts of patients with DCM with end-stage heart failure. Correction of the TPM1-L185F mutation in DCM patient–derived induced pluripotent stem cells, treatment with a peptide, Rho activator II, or iron supplementation rescued the molecular disease pathway and recovered contractility. Phenocopying the effects of the TPM1-L185F mutation into WT induced pluripotent stem cell–derived cardiomyocytes could be ameliorated by iron supplementation. Conclusions: Our findings suggest that impaired endocytosis and cargo transport resulting in subcellular iron deficiency could be a relevant pathomechanism for patients with DCM carrying inherited mutations. Insight into this molecular mechanism may contribute to the development of treatment strategies and risk management in heart failure.
- 7 July 2023
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 133 (2) , E19-E46
An Alternative Mechanism of Subcellular Iron Uptake Deficiency in Cardiomyocytes
Background: Systemic defects in intestinal iron absorption, circulation, and retention cause iron deficiency in 50% of patients with heart failure. Defective subcellular iron uptake mechanisms that are independent of systemic absorption are incompletely understood. The main intracellular route for iron uptake in cardiomyocytes is clathrin-mediated endocytosis. Methods: We investigated subcellular iron uptake mechanisms in patient-derived and CRISPR/Cas–edited induced pluripotent stem cell–derived cardiomyocytes as well as patient-derived heart tissue. We used an integrated platform of DIA-MA (mass spectrometry data-independent acquisition)–based proteomics and signaling pathway interrogation. We employed a genetic induced pluripotent stem cell model of 2 inherited mutations ( TnT [ troponin T ]-R141W and TPM1 [ tropomyosin 1 ]-L185F) that lead to dilated cardiomyopathy (DCM), a frequent cause of heart failure, to study the underlying molecular dysfunctions of DCM mutations. Results: We identified a druggable molecular pathomechanism of impaired subcellular iron deficiency that is independent of systemic iron metabolism. Clathrin-mediated endocytosis defects as well as impaired endosome distribution and cargo transfer were identified as a basis for subcellular iron deficiency in DCM-induced pluripotent stem cell–derived cardiomyocytes. The clathrin-mediated endocytosis defects were also confirmed in the hearts of patients with DCM with end-stage heart failure. Correction of the TPM1-L185F mutation in DCM patient–derived induced pluripotent stem cells, treatment with a peptide, Rho activator II, or iron supplementation rescued the molecular disease pathway and recovered contractility. Phenocopying the effects of the TPM1-L185F mutation into WT induced pluripotent stem cell–derived cardiomyocytes could be ameliorated by iron supplementation. Conclusions: Our findings suggest that impaired endocytosis and cargo transport resulting in subcellular iron deficiency could be a relevant pathomechanism for patients with DCM carrying inherited mutations. Insight into this molecular mechanism may contribute to the development of treatment strategies and risk management in heart failure.
- Open Access
- 5 April 2023
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 118 (1) , 1-22
Electrophysiological and calcium-handling development during long-term culture of human-induced pluripotent stem cell-derived cardiomyocytes
Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are increasingly used for personalised medicine and preclinical cardiotoxicity testing. Reports on hiPSC-CM commonly describe heterogenous functional readouts and underdeveloped or immature phenotypical properties. Cost-effective, fully defined monolayer culture is approaching mainstream adoption; however, the optimal age at which to utilise hiPSC-CM is unknown. In this study, we identify, track and model the dynamic developmental behaviour of key ionic currents and Ca2+-handling properties in hiPSC-CM over long-term culture (30–80 days). hiPSC-CMs > 50 days post differentiation show significantly larger ICa,L density along with an increased ICa,L-triggered Ca2+-transient. INa and IK1 densities significantly increase in late-stage cells, contributing to increased upstroke velocity and reduced action potential duration, respectively. Importantly, our in silico model of hiPSC-CM electrophysiological age dependence confirmed IK1 as the key ionic determinant of action potential shortening in older cells. We have made this model available through an open source software interface that easily allows users to simulate hiPSC-CM electrophysiology and Ca2+-handling and select the appropriate age range for their parameter of interest. This tool, together with the insights from our comprehensive experimental characterisation, could be useful in future optimisation of the culture-to-characterisation pipeline in the field of hiPSC-CM research.
- 5 April 2023
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 118 (1) , 1-22
Open AccessElectrophysiological and calcium-handling development during long-term culture of human-induced pluripotent stem cell-derived cardiomyocytes
Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are increasingly used for personalised medicine and preclinical cardiotoxicity testing. Reports on hiPSC-CM commonly describe heterogenous functional readouts and underdeveloped or immature phenotypical properties. Cost-effective, fully defined monolayer culture is approaching mainstream adoption; however, the optimal age at which to utilise hiPSC-CM is unknown. In this study, we identify, track and model the dynamic developmental behaviour of key ionic currents and Ca2+-handling properties in hiPSC-CM over long-term culture (30–80 days). hiPSC-CMs > 50 days post differentiation show significantly larger ICa,L density along with an increased ICa,L-triggered Ca2+-transient. INa and IK1 densities significantly increase in late-stage cells, contributing to increased upstroke velocity and reduced action potential duration, respectively. Importantly, our in silico model of hiPSC-CM electrophysiological age dependence confirmed IK1 as the key ionic determinant of action potential shortening in older cells. We have made this model available through an open source software interface that easily allows users to simulate hiPSC-CM electrophysiology and Ca2+-handling and select the appropriate age range for their parameter of interest. This tool, together with the insights from our comprehensive experimental characterisation, could be useful in future optimisation of the culture-to-characterisation pipeline in the field of hiPSC-CM research.